Genmab As (GNMSF) Stock Rating Upgraded by Zacks Investment Research

Genmab As (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. downgraded shares of Genmab As from an “overweight” rating to a “neutral” rating in a research report on Friday, October 6th.

Genmab As (OTCMKTS:GNMSF) opened at $167.50 on Wednesday. Genmab As has a 1 year low of $163.00 and a 1 year high of $239.75. The stock has a market cap of $10,470.00 and a price-to-earnings ratio of 59.23.

TRADEMARK VIOLATION NOTICE: “Genmab As (GNMSF) Stock Rating Upgraded by Zacks Investment Research” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3126289/genmab-as-gnmsf-stock-rating-upgraded-by-zacks-investment-research.html.

Genmab As Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).

Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.